continued good interest for afternoon, everyone. in Bioventus. Thank Dave, your you thanks, and Well,
Let I'm leading its thrilled saying that Bioventus be by and to team. me begin back talented
I my business to our a to year. performance, discussing remainder discuss lay want take on minutes our quarter's the for to the few Before of priorities the since returning out and perspective
opportunity company, our our Over new we and employees the with near-term move members business. my the the of ability had meet month, across growth team am who since the the reconnect the to revenue from Despite to their retirement as understand and confident in opportunities XXXX, I've on perspective Bioventus past forward. leverage and challenges, I joined to earnings reduce in
in for execution, participate provide large of Most markets growing differentiated employees we are delivering commitments, and we business, enhancing our truly on focused our a on innovative challenges business. our and our products team importantly, and understand Across have who current our dedicated patients.
to aggressively elements team, stabilize returning our plans address plan on to are profitable and are to now address and In role the CEO, issues predictability. My the and I the recent on action then leadership issues growth prioritizing and is our of impacting to positive look team profitability here performance. my build and our impacting quickly as the that focus
loan be will of on growth, attention laser-like remaining compliant on a deliver but growth not amended we with and Our profitable have ensuring our we focus bank leverage. driving just covenants down and
of rebuild quarters we the the believe investors. course year we the will several next regain to our past look will we our of over in single all credibility reverse with sheet and balance a the headwinds While not quarter,
business. operating necessary our closing noncore following we'll efficiency, HA strategic of increase and XXXX, franchise; prioritize third, business throughout actions improve and wound dissecting impact to divestiture the the of the the the evaluate areas: of to and first, divestiture the improve franchise our recent the examining headwinds our Over remainder opportunities our in continuing executing second, assets profitability, predictability; after and of controls to
provide on our three quarter. recent context Let before further reviewing areas these me
one the us of volume payer, recent we the private to recent increase understand through them assess and profitability. that quality contracts a quarters bolster partner increased to of volume the most with and It's to changes has changes important their due to potential First, resulted initiated to in review private HA procedural the strategic payer to franchise, from to impacting continue in improve invoicing. in we've highlight our
franchise. the that we and lower expect in can impact further must but to evaluate private months the steps uncertainty, evaluation we began future third quarter based. on renegotiated an would These on few addition, call payer given smaller aspects update pricing which as that assess over consultant, we and of an through rates coming provide the In to the with improve on our next reduce impact see increased second Working will rebates we the external contracts. additional HA expect sales our are our conduct volume earnings results quarter rebate the we
we announcement simplifies by encouraged our Second, our the management which sheet. remaining focus franchise also and wound attention The business allows our additional our business, the on of of balance of divestiture are liquidity areas wound improves week's strategic portfolio. to regarding delevers divestiture and last our our
- additional use on remove approximately which sales At $XX potentially receive, repay milestones. expect quarterly the the or from closing, debt will and need This repayment the three to we quarters the next our amortization quarterly with repay potential to debt. loan quarters proceeds we to to pay to million, fees, term after plan for
sheet divestiture the is While a assets. our noncore additional continue step, we divestiture to to opportunities positive wound of evaluate balance strengthen will further through
prioritization the divesting we win. only the in for negotiation attractive strategically value. at we will we of any an business be Still, Our define areas areas our on remain business believe can will we and noncore simplify that disciplined assets placed will investment which and where as and emphasis consider
our start area arose inefficiencies operating our we due of opportunities the of across throughout exploring and At The business employee turnover. began controls involves year, recent focus where the and business. to increase improve work to and third acquisitions profitability select areas efficiency our
be additional make enable throughout efforts savings cost beginning potential to to the required our in year. drive us some find and will and internal inefficiencies, addressing and working controls. these back-office We're steady performance Those improved enhance operational progress capital work processes should but
complete facility continue In the of by Misonix the expect to addition, manufacturing of Memphis. the we of to integration move new with the year to end our the in
quarter Now let to first turn our me results.
period $XXX revenues earnings a Mark quarter, million compared laid the call. in For ago, last out the with year to the quarterly same line our X% was which on increased of commentary
the $XX to prior EBITDA adjusted our compared to million importantly, More increased year. million $X in
above acid. to this disciplined our rise to in impacted differentiation. related Durolane continue required of expectations impacted Once for given payer due accrual control treatments, pain The expenses. volume strong clinical be was Across was contracts private Adjusted hyaluronic our EBITDA for we shift rate the impact by to sales, us increase its but again, HA volume less growth to of the headwinds. mitigate helped to
quarter, Consistent erosion from drive with through portfolio, our progress selling our we last we subside will volume XXXX. price, growth. share growth, an HA lower across anticipate as price increase we Meanwhile, to combined market in message with believe
improved impact of However, turnaround of driven we to the of low-double high-single and next year to this the in reduction and revenue expect stabilization to fourth by by due HA revenue first begin growth. expect volume HA to We and quarter quarter price year lower see the growth do overall selling price. of digits
Now turning to Surgical Solutions.
we quarter, Growth bone was substitutes deliver again OsteoAmp strong continued Flowable. across double-digit the driven growth. to For graft organic by once
Additionally, digits. our ultrasonics portfolio grew high-single
anticipated substitute offset portfolio to bone losses graft the the we as some year. slowdown expect the to due half large second quarter, customer our increased in ahead we Looking wins recent into churn, second are move but account to of these
the we year. that organic growth growth will double-digit for overall the our While current likely continue lower will be full forecast quarter, in
both smaller share and ultrasonics overall penetration backdrop Our graft and continued growth a substitutes. growth our market and rates bone for market market provide strong across
to improving as to physicians Restorative we continue grew and realignment the Advanced partially digits, the after challenges in chain Exogen XXXX. with revenue of the and double regulatory the was fourth benefit experiencing business Rehabilitation. from quarter. Within similar the approval reflects organic disruptions experienced our we're force start prior trend associated revenue Revenue at year sales supply reengage growth driven recovery Therapies, by across
portfolio, When and basis growth approximately the Therapies across Restorative points total vertical. divested wound Exogen XXX Advanced higher excluding Rehabilitation was than recently our
drive We expect growth mid-single-digit growth with portfolio. will our stability overall for in entire Restorative Therapies Advanced Exogen for Rehabilitation combined
headwinds Growth growth as we Rehabilitation maintaining Finally, well International graft in XX%. regulatory year. segment strong our segment EU substitutes. grew Constant International our growth was currency anticipate was recovery as driven our and proceed related growth MDR the We double-digit in as from bone through Durolane in the XX%. by Advanced
address to business to am I'm repeat move team's Finally, again. be our and ability our leading let I forward. confident Bioventus immediate me in the how challenges excited
our driving those work We areas profitability efficiencies improving balance increased and and confidence in are margins, aggressively enhancing your as our to operational restore in Bioventus. prioritizing we meaningful most sheet,
Now the over to Mark. let me call turn